Importance There is a need for a more refined, molecularly based classification model for
glioblastoma (GBM) in the temozolomide era. Objective To refine the existing clinically …

A recent nomogram for glioblastoma (GBM) was designed to incorporate methylguanine-
DNA methyltransferase (MGMT) methylation status in trial patients receiving temozolomide …

Background and purpose A novel molecular recursive partitioning analysis classification has
recently been reported integrating the MGMT promoter methylation (MGMTmeth) and IDH1 …

Objective Several survival prediction models for patients with glioblastoma have been
proposed, but none is widely used. This study aims to identify the predictors of overall …

Since the development of the Radiation Therapy Oncology Group-Recursive Partitioning
Analysis (RTOG-RPA) risk classes for high-grade glioma, radiation therapy in combination …

Background and purpose To refine the recursive partitioning analysis (RPA) classification for
glioblastoma incorporating the MGMT methylation and IDH1 mutation status. Methods and …

Purpose: The methylation status of the O6-methylguanine DNA methyltransferase (MGMT)
gene promoter is predictive for benefit from temozolomide in glioblastoma (GBM). A clinically …

We attempted to establish a magnetic resonance imaging (MRI)-based radiomic model for
stratifying prognostic subgroups of newly diagnosed glioblastoma (GBM) patients and …

Uncertainty exists about the adequate treatment of adult patients with unresectable, primary,
biopsy-proven glioblastoma multiforme (GBM), because the different options for this group of …

Purpose: Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after
temozolomide chemoradiotherapy (TMZ/RT→ TMZ) has been studied in retrospective and …